Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a Phase 3 ...

Following the FDA approval of linvoseltamab (Lynozyfic; Regeneron) for heavily pretreated multiple myeloma, Sundar Jagannath, MBBS, highlights its potential for earlier use, increased accessibility, ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most profitable biotech stocks to invest in now. Canaccord ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

Novo Nordisk ( NVO 1.34%) and Regeneron Pharmaceuticals ( REGN -0.27%), two leading drugmakers, have underperformed for most ...

Regeneron now plans to use a previously granted priority review voucher to expedite the review for the 8-mg regimen of Eylea, CEO Leonard Schleifer, M.D., Ph.D., told investors during an earnings ...

While Regeneron's COVID-19 treatment is undoubtedly responsible for the largest drop in sales, even the company's flagship eye medication, Eylea, declined by 2%. In the first quarter of this year ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter ...

Regeneron intends for 23andMe to continue its consumer genome services without interruption. The transaction, pending bankruptcy court and regulatory approvals, is expected to close in the third ...

Regeneron rose to prominence in the 1990s and early 2000s with its genetic research in mice. The company engineered the mouse's immune system to be more humanlike, which helped test drug candidates.

Regeneron's antibody cocktail protects against COVID-19 for up to 8 months, giving hope to the immunocompromised By Kevin Dunleavy Nov 8, 2021 9:17am antibodies COVID-19 George Yancopoulos Len ...